66 research outputs found
Association between work-related difficulties and dual-task ability in people with multiple sclerosis
No full textAssociation between work-related difficulties and dual-task ability in people with multiple sclerosis
No full textDual‐task difficulties as a risk factor for unemployment in people with multiple sclerosis
No full textBackground No study has investigated the impact of dual-tasking difficulties as a risk factor for unemployment in people with multiple sclerosis (pwMS). The aim was to examine the influence of dual-task performance on employment status and work difficulties and to identify the predictors of employment status in pwMS. Methods Eighty-four pwMS, including 42 employed and 42 unemployed, participated in the study. Dual-task difficulties were assessed using the Dual-task Impact on Daily-living Activities-Questionnaire (DIDA-Q), while dual-task performance was evaluated through the 30-second Walk Test and Nine-Hole Peg Test, incorporating a cognitive task. Walking and cognitive function were also measured. Results Employed pwMS had better scores in walking, cognitive function, single and dual-task performance than unemployed pwMS (p < .05). Lower scores in walking (odds ratio [OR] = 1.81, p < .001) and upper extremity-related (OR = 1.44, p = .019) dual-task performance and higher scores in the cognitive subscale of the DIDA-Q questionnaire (OR = 1.20, p = .037) were significantly associated with higher odds of being unemployed. Among employed pwMS, DIDA-Q subscales showed moderate-to-strong correlations with MSWSDQ-23 scores. The other variables showed weak-to-moderate correlations with subscale and total scores of MSWSDQ-23. Conclusion Cognitive function, as opposed to motor function, has been found to be a significant predictor of unemployment in pwMS
Examining stage plays of Hüseyin Cavid titled Uçurum and Şeydal
No full textHüseyin Cavid, 20. yüzyıl başlarından itibaren faaliyet göstermeye başladığı edebi kişiliği yazarlığı ve şairliğiyle Azerbaycan sanat ve edebiyat hayatına büyük katkılar yapmış önemli bir şahsiyettir. Doğu toplumları içinde meydana getirilen ilk manzum piyesin de yazarıdır. İçinde yaşadığı toplumun aksaklıklarını gerek mizah yoluyla gerekse dram yoluyla ortaya koymaktan çekinmeden sahne eserleri vasıtasıyla halkını bilinçlendirmeyi gaye edinmiştir. Bu çalışma Hüseyin Cavid'in Uçurum ve Şeyda isimli dram türündeki piyeslerinin Azerbaycan Türkçesinden Türkiye Türkçesine aktarılması ve muhteva bakımından incelenmesinden ibarettir. Hüseyin Cavid'in bahsedilen iki piyesinde Azerbaycan 'ın 20. yüzyıl başlarındaki toplum yapısına ve hayat tarzına ışık tutulmuş, toplumsal gelişmenin önünde engel olarak görülen bazı yanlış tutumlar gerçekçi bir üslupla tenkit edilmiştir.Hüseyin Cavid is an important personality as an author and poet who contributed to Azerbaijani art and literature which he was actively producing since the beginning of the 20th century. He is also the writer of the first poetic stage play created in Eastern communities. He aimed at raising awareness of his community through stage plays without hesitation to elicit flaws of the community he lived in through both humour and drama. This study consists of translating Hüseyin Cavid's stage plays in the type of drama titled "Uçurum" and "Şeyda" from Azerbaijani Turkish to Turkey Turkish and examining their contents. In two stage plays in question, Hüseyin Cavid sheds light on community structure and life style of Azerbaijan in the beginning of the 20th century and criticizes some attitudes which have been perceived as impediment to development, in a realistic manner
Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study
No full textIntroduction: Ocrelizumab is an effective treatment in reduc-ing relapse rate and slowing disability progression in the short term.Aims:To evaluate disability progression in people with multiple sclerosis (pwMS) treated with ocrelizumab.Methods: pwMS candidates for ocrelizumab treatment were enrolled in this prospective single-center observational study and followed up for two years. Disability was evaluated with Expanded Disability Status Scale (EDSS), Timed 25 Feet Walk (T25F) test, 9 Hole Peg Test (9HPT), Timed up and Go (TUG) test, and Twelve Item MSWalking Scale (MSWS) survey. First assessments were done before the ocrelizumab initiation and every six months after-ward. Patients with secondary progressive and primary progres-sive MS were analyzed as progressive MS (PMS). A change of %20 in test performance time was considered clinically significant.Results: 107 PMS patients were enrolled. When analyzed sepa-rately, there was no significant difference between baseline and two-year follow-up scores in total EDSS and functional subscores (p>0.05). PMS showed significant worsening in the TUG test (p=0.043) in the first, T25FW (p=0.03) in the second, and MSWS-12 scores in the first (N:99, p:0,006) and the second (N:43 p:0.002) years of evaluation in comparison to baseline results. Of 53 PMS evaluated in the second year, 39 had not shown significant change on 9HPT results, two had improved performance, and 12 had a %20 increase in the test time compared to baseline. Overall 9HPT results did not show a significant change in two-year follow-up (p>0.05).Conclusions: Although ocrelizumab does not show favorable results in the lower extremity functions in the progressive form, it could halt the disability accumulation in the upper extremity in the long term. Disclosure Cavid Baba: nothing to disclose Ergi Kaya: nothing to disclose Sinem Ozcelik: nothing to disclose Asiye Tuba Ozdogar: nothing to disclose Ozge Sagici: nothing to disclose Seda Dastan: nothing to disclose Serkan Ozakbas: nothing to disclose</p
Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location.
No full textAn analysisof the outer space regime set forth by the United Nations treaties in the context of the International Law
No full textSpace Law, after improvements on the space technology in the 20th century, has been shaped through General Assembly resolutions and international treaties. Besides the contribution of the United Nations, other international organizations? and doctrine?s contributions on the shaping of Space Law could not be denied. The main objective of the author is to examine the United Nations Space Treaties which could be described as the main sources of Space Law. In this context, measures of the United Nations Treaties, resolutions of the United Nations General Assembly and linkage between these Treaties and Resolutions has been discussed firstly. Then measures of the United Nations Treaties has been interpreted and critised in the light of current legal matters regarding space and space activities.Uzay Hukuku, 20. yüzyılda uzay teknolojisine ilişkin gelişmelerden sonra Birleşmiş Milletler bünyesinde alınan Genel Kurul kararları ile uluslararası antlaşmalarla oluşmaya başlamıştır. Uzay Hukuku'nun ortaya çıkışında Birleşmiş Milletlerin katkısının yanında, diğer uluslararası örgütlerin ve doktrinin katkısı da yadsınamaz. Yazarın amacı, Uzay Hukuku'nun temel kaynağı olarak nitelendirilebilecek uzaya ilişkin Birleşmiş Milletler Antlaşmaları'nı incelemektir. Bu kapsamda, öncelikle Birleşmiş Milletler Antlaşmaları'nın getirdiği düzenlemeler, Birleşmiş Milletler Genel Kurul Kararları ile getirilen ilkeler ve söz konusu antlaşmalar ile ilkelerin ilişkisi ele alınmıştır. Sonrasında Birleşmiş Milletler Antlaşmaları'nda yer alan düzenlemeler, uzaya ve uzay faaliyetlerine ilişkin mevcut hukuki sorunlar karşısında değerlendirilmiş ve eleştirilmiştir
Prevalence and determinants of falls in persons with multiple sclerosis without a clinical disability
No full textBackground: Falls are common in persons with Multiple Sclerosis (pwMS) and lead to destructive results, specifically with increasing disability. However, there is only scarce data investigating prevalence and determinants of falls in pwMS without a clinical disability. Therefore, this study aimed to investigate proportion of fallers and related factors in pwMS without a clinical disability. Methods: One hundred and four pwMS with no clinical disability (EDSS?1.5) were recruited in this crosssectional study. The outcome measures comprised of the Timed 25-Foot Walk (T25FW), Six Minute Walk Test (6MWT), Timed Up and Go Test (TUG), Multiple Sclerosis Walking Scale (MSWS-12), Single Leg Stance Test (SLS), Activities-Specific Balance Confidence Scale (ABC), Symbol Digit Modalities Test (SDMT), Modified Fatigue Impact Scale (MFIS), and Beck Depression Inventory-II (BDI-II). The number of falls during the last three months was recorded. Results: : Twenty-five percent of the pwMS reported at least one fall in the last three months. The TUG and MSWS-12 scores were significantly greater in the fallers compared to non-fallers (p<0.05). Whereas the fallers had significantly less ABC scores (p<0.05). Increasing TUG and MSWS-12 score and decreasing ABC score was related with increased risk of being classified as a faller adjusting for EDSS score. Conclusion: The present findings highlight that falls are frequent problem for pwMS, even if they do not have a clinical disability. Therefore, falls prevention strategies are also required in the early stages of the disease in clinical practice. The ABC scale, MSWS-12, and TUG test can be used by the clinicians and researchers to predict potential fallers of the pwMS without a clinical disability
Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort
No full textBackground Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system. DMTs effectively reduce the annual relapse rate-thus reducing disease activity-and, to a lesser extent, some DMTs prevent disease progression in some people with MS. Monitoring the efficacy of DMTs with no evidence disease activity (NEDA) provides an objective perspective for evaluating treatment success. Objective Our goal is to detect the prevalence of NEDA-3 in people with MS treated with self-injectable DMTs at two years and 10 years in a retrospective study. Methods The treatment continuation rates and NEDA-3 parameters in the 2nd and 10th years were evaluated. Results A total of 1032 patients diagnosed with RRMS were included in the study, and 613 patients (59.3%) continued with treatment after 10 years. In the first two years, NEDA-3 was detected in 321 patients (52.4%), and 112 of the 613 patients continued with self-injectable DMTs at the end of 10 years (18.3%). The rate of NEDA-3 in patients starting treatment over the age of 35 was 15.1% compared to that in the patient group starting treatment aged 34 or less at 20.2% (p = .004). Conclusion Our study includes the most comprehensive NEDA-3 data from real world evidence and supports the idea that NEDA-3 can be an effective early predictor of progression-free status at treatment follow-up of up to 10 years
- …
